MedTrace Logo

A Self Selected Population Study of Undiagnosed NAFLD and NASH, Using an Echosens FibroScan, in at Risk Populations

NCT03726827 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1006

Last updated 2019-09-23

No results posted yet for this study

Summary

Liver disease (NAFLD) and (NASH) are a rapidly increasing population health threat driven primarily by diet and lifestyle. Fibrotic liver disease, culminating in cirrhosis, is frequently asymptomatic so it is common for a patient to first learn of what is a life threatening condition by being told that they have cirrhosis. Management and treatment of cirrhosis is complex and very costly with the only current cure being a very expensive transplant for end stage liver disease. The SUNN study seeks to perform Fibroscan wellness testing on at risk but asymptomatic self selected patients in the general population to identify disease early and to triage patients toward care or educational tools based upon test results. No personally identifiable information will be collected but demographic and test results will be imported into a registry for data analysis. Results of the study will guide development of screening protocols to identify early stage disease in a wellness screening model.

Conditions

  • NAFLD
  • NASH - Nonalcoholic Steatohepatitis
  • Cirrhosis, Liver
  • Fatty Liver

Interventions

OTHER

Fibroscan screening

A single Fibroscan screening for fat content and liver stiffness

Sponsors & Collaborators

  • Fatty liver Foundation

    lead OTHER

Principal Investigators

  • Wayne Eskridge, BS · Fatty liver Foundation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2019-08-30
Completion
2019-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03726827 on ClinicalTrials.gov